Late-life semaglutide treatment slows ageing and extends lifespan in female mice.

Yufan Feng, Marine Barthez, Yifei Wang, Yibing Chen, Huixian Qiu, Chih-Ling Wang, Kartoosh Heydari, Melaine Delcroix, Lene Juel Rasmussen, Vilhelm A Bohr, Danica Chen

Department of Metabolic Biology and Nutrition, University of California, Berkeley, CA, USA.Department of Metabolic Biology and Nutrition, University of California, Berkeley, CA, USA. · pubmed

Paper

Abstract

Pharmacological glucagon-like peptide-1 receptor (GLP-1R) activation reduces food intake and is an effective therapy for type 2 diabetes and obesity

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Late-life semaglutide treatment slows ageing and extends lifespan in female mice. This study provides direct evidence that GLP-1 receptor agonists, a class of drugs already in clinical use for metabolic diseases, can extend lifespan and slow aging markers when administered in late life, suggesting a potential therapeutic avenue for longevity beyond simple weight management.

Author of this paper? Send a correction.